| Dir : /home/ithome/mail/cur/ |
| Server: Linux host100322.itwesthosting.com 3.10.0-1160.144.1.el7.tuxcare.els4.x86_64 #1 SMP Tue Apr 7 08:40:40 UTC 2026 x86_64 IP: 144.91.64.173 |
| Dir : /home/ithome/mail/cur/1757971030.M41796P975.host100322.itwesthosting.com,S=11871,W=12000:2, |
Return-Path: <editorial@currentneuropharmacology.net>
Delivered-To: ithome@host100322.itwesthosting.com
Received: from host100322.itwesthosting.com
by host100322.itwesthosting.com with LMTP
id lAJeAlaCyGjPAwAAp0YrwQ
(envelope-from <editorial@currentneuropharmacology.net>)
for <ithome@host100322.itwesthosting.com>; Mon, 15 Sep 2025 23:17:10 +0200
Return-path: <editorial@currentneuropharmacology.net>
Envelope-to: viktor.vidovic@bolnica-lipik.hr
Delivery-date: Mon, 15 Sep 2025 23:17:10 +0200
Received: from [122.50.0.137] (port=57842 helo=mhms.virtual-mail-020.net)
by host100322.itwesthosting.com with esmtps (TLS1.2) tls TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384
(Exim 4.96.2)
(envelope-from <editorial@currentneuropharmacology.net>)
id 1uyGZQ-0000FZ-1n
for viktor.vidovic@bolnica-lipik.hr;
Mon, 15 Sep 2025 23:17:09 +0200
DKIM-Signature: v=1; a=rsa-sha256; q=dns/txt; c=relaxed/relaxed;
d=currentneuropharmacology.net; s=default; h=Content-Type:MIME-Version:
List-Unsubscribe:Message-ID:Subject:From:To:Date:Sender:Reply-To:Cc:
Content-Transfer-Encoding:Content-ID:Content-Description:Resent-Date:
Resent-From:Resent-Sender:Resent-To:Resent-Cc:Resent-Message-ID:In-Reply-To:
References:List-Id:List-Help:List-Subscribe:List-Post:List-Owner:List-Archive
; bh=l5uqmqAZY7dH0LwUw/X8nLStyt6uYv4XWVoOr9lPIv8=; b=pkVY+VrZ3z8AEU5cRK6OfjFr
fFfTa0xdVJAC/h+xl3gwRUB3lydo8XsNAMi0ClnzW4eu6ZydvKukVZb3A0xGEvF5+0XE+okWuIbG8
nHHoP0VCEbjIGmkzACnVPlcNxj+7VfMYrQoump1DyAWdMHK1BOtVvKO+9KyBynWjiulG8il/FAQzI
a0zlJSJY3bFBGP2maCHP14sh6yq6q64t1wjR+48lYuxG2dfYtfI/S5uUyTI2ORoO0OIpBRJ1ckvFu
uKOBjYS9h5xhNRL7+UKvyvGKf/Uaukp1/Dl858yF3vKHoCL5ukPo/oZlxPmYQ+kGq0o+Hprh2HMKv
BqeW6aKiwQ==;
Received: from [122.50.0.137] (port=38960 helo=mhms.virtual-mail-020.net)
by mhms.virtual-mail-020.net with esmtpsa (TLS1.3) tls TLS_AES_256_GCM_SHA384
(Exim 4.98.2)
(envelope-from <editorial@currentneuropharmacology.net>)
id 1uyGZL-0000000CzrO-1Ecv
for viktor.vidovic@bolnica-lipik.hr;
Tue, 16 Sep 2025 02:17:04 +0500
Date: Mon, 15 Sep 2025 21:16:56 +0000
To: viktor.vidovic@bolnica-lipik.hr
From: Current Neuropharmacology <editorial@currentneuropharmacology.net>
Subject: [CN-102-116-16808-42735406] - Invitation to Contribute: Dr. V. Vidovi on Current Neuropharmacology
Message-ID: <r0IzuTokSg2puKj0PjtJ8HXq1go3KofDbrQ1u5XPc@mhms.virtual-mail-020.net>
X-Mailer: PHPMailer 6.9.1 (https://github.com/PHPMailer/PHPMailer)
List-Unsubscribe: <https://currentneuropharmacology.net/contribution-unsubscribe-request.php?key=0370e3fd51c01c228d60134d86ad4fef967044d72b0e21f910ac0085b350c4ca>
MIME-Version: 1.0
Content-Type: text/html; charset=iso-8859-1
X-AntiAbuse: This header was added to track abuse, please include it with any abuse report
X-AntiAbuse: Primary Hostname - mhms.virtual-mail-020.net
X-AntiAbuse: Original Domain - bolnica-lipik.hr
X-AntiAbuse: Originator/Caller UID/GID - [47 12] / [47 12]
X-AntiAbuse: Sender Address Domain - currentneuropharmacology.net
X-Get-Message-Sender-Via: mhms.virtual-mail-020.net: authenticated_id: editorial@currentneuropharmacology.net
X-Authenticated-Sender: mhms.virtual-mail-020.net: editorial@currentneuropharmacology.net
X-Source:
X-Source-Args:
X-Source-Dir:
X-Spam-Status: No, score=1.9
X-Spam-Score: 19
X-Spam-Bar: +
X-Ham-Report: Spam detection software, running on the system "host100322.itwesthosting.com",
has NOT identified this incoming email as spam. The original
message has been attached to this so you can view it or label
similar future email. If you have any questions, see
root\@localhost for details.
Content preview: Reference #: CN-102-116-16808-42735406 Call for Papers & Thematic
Issues Current Neuropharmacology (Clarivate Impact Factor: 5.3, Scopus Cite
Score: 8.7) Dear Dr. V. Vidovi,
Content analysis details: (1.9 points, 5.0 required)
pts rule name description
---- ---------------------- --------------------------------------------------
0.0 URIBL_BLOCKED ADMINISTRATOR NOTICE: The query to URIBL was
blocked. See
http://wiki.apache.org/spamassassin/DnsBlocklists#dnsbl-block
for more information.
[URIs: currentneuropharmacology.net]
-0.0 SPF_PASS SPF: sender matches SPF record
-0.0 SPF_HELO_PASS SPF: HELO matches SPF record
0.0 RCVD_IN_VALIDITY_RPBL_BLOCKED RBL: ADMINISTRATOR NOTICE: The
query to Validity was blocked. See
https://knowledge.validity.com/hc/en-us/articles/20961730681243
for more information.
[122.50.0.137 listed in bl.score.senderscore.com]
0.1 MIME_HTML_ONLY BODY: Message only has text/html MIME parts
0.0 HTML_MESSAGE BODY: HTML included in message
-0.1 DKIM_VALID Message has at least one valid DKIM or DK signature
-0.1 DKIM_VALID_EF Message has a valid DKIM or DK signature from
envelope-from domain
0.1 DKIM_SIGNED Message has a DKIM or DK signature, not necessarily
valid
-0.1 DKIM_VALID_AU Message has a valid DKIM or DK signature from
author's domain
0.0 RCVD_IN_VALIDITY_CERTIFIED_BLOCKED RBL: ADMINISTRATOR NOTICE:
The query to Validity was blocked. See
https://knowledge.validity.com/hc/en-us/articles/20961730681243
for more information.
[122.50.0.137 listed in sa-trusted.bondedsender.org]
2.0 RDNS_NONE Delivered to internal network by a host with no rDNS
X-Spam-Flag: NO
X-From-Rewrite: unmodified, forwarded message
<html>
</body>
<div style=' width:100%; padding:20px;text-align: justify;'>
<strong>Reference #: CN-102-116-16808-42735406</strong>
<br/>
<br/>
<p><p style="text-align: center;"><em><strong><span style="color: rgb(0, 0, 0); font-family: 'times new roman', times, serif; font-size: 12pt;">Call for Papers & Thematic Issues</span></strong></em><br><em><strong><span style="color: rgb(0, 0, 0); font-family: 'times new roman', times, serif; font-size: 12pt;">Current Neuropharmacology</span></strong></em><br><em><strong><span style="color: rgb(0, 0, 0); font-family: 'times new roman', times, serif; font-size: 12pt;">(Clarivate Impact Factor: 5.3, Scopus Cite Score: 8.7)</span></strong></em></p>
<p><span style="color: rgb(0, 0, 0); font-family: 'times new roman', times, serif; font-size: 12pt;">Dear Dr. V. Vidovi,</span></p>
<p><span style="font-family: 'times new roman', times, serif; font-size: 12pt; color: rgb(0, 0, 0);">This is a call for papers & thematic issues for the journal <strong><em>Current Neuropharmacology </em>(CN)</strong>. The journal is in its 23rd year of publication and has been indexed in all prominent indexing agencies including <span style="text-decoration: underline;"><strong>Science Citation Index Expanded (SciSearch), MEDLINE/PubMed, Scopus</strong></span> etc.</span></p>
<p><span style="font-family: 'times new roman', times, serif; font-size: 12pt; color: rgb(0, 0, 0);"><em><strong>Current Neuropharmacology</strong></em> aims to provide current, comprehensive/mini-reviews. The reviews cover the fields of molecular, cellular, and systems/behavioural aspects of neuropharmacology and neuroscience. Moreover, position papers and research articles/clinical trials of great novelty and scientific interest might occasionally be considered for publication, along with guest-edited issues in all areas of neuropharmacology and neuroscience.</span></p>
<p><span style="font-family: 'times new roman', times, serif; font-size: 12pt; color: rgb(0, 0, 0);">Submission of an article or abstract may be undertaken through our online submission system. All submitted manuscripts are peer-reviewed prior to a possible decision on acceptance for publication.</span></p>
<p><span style="font-family: 'times new roman', times, serif; font-size: 12pt; color: rgb(0, 0, 0);">If you are interested in guest editing a thematic issue, then please submit your proposal by return email. Thematic issue proposals should contain title, aims and scope of the theme issue, with the list of contributors (with corresponding authors having preferable <strong>h-index 15 or above 15</strong>) and tentative manuscript titles</span>.</p>
<p><span style="text-decoration: underline;"><strong><span style="font-family: 'times new roman', times, serif; font-size: 12pt; color: rgb(0, 0, 0); text-decoration: underline;">Benefits for Authors & Guest Editors:</span></strong></span></p>
<ul>
<li style="color: rgb(0, 0, 0);"><span style="font-family: 'times new roman', times, serif; font-size: 12pt; color: rgb(0, 0, 0);">Articles will be published online within <strong>40 days</strong> of final acceptance.</span></li>
<li style="color: rgb(0, 0, 0);"><span style="font-family: 'times new roman', times, serif; font-size: 12pt; color: rgb(0, 0, 0);">Free Online Subscription to the Guest Editors for their thematic issue, once it is published.</span></li>
</ul>
<p style="text-align: left;"><span style="text-decoration: underline; font-family: 'times new roman', times, serif; font-size: 12pt;"><strong><span style="color: rgb(0, 0, 0); text-decoration: underline;">To ensure better and timely communication with the editorial office, please provide your active WhatsApp/WeChat number and link to your LinkedIn profile while replying to this email.</span></strong></span></p>
<p><span style="color: rgb(0, 0, 0); font-family: 'times new roman', times, serif; font-size: 12pt;">We look forward to receiving your positive response.</span></p>
<p><span style="color: rgb(0, 0, 0); font-family: 'times new roman', times, serif; font-size: 12pt;">Sincerely,</span></p>
<p><span style="font-family: 'times new roman', times, serif; font-size: 12pt;"><em><strong><span style="color: rgb(0, 0, 0);">Editorial Office</span></strong></em></span></p>
<p><span style="font-family: 'times new roman', times, serif; font-size: 12pt;"><em><strong><span style="color: rgb(0, 0, 0);">Current Neuropharmacology (CN)</span></strong></em></span></p>
<p style="text-align: center;"><span style="color: rgb(0, 0, 0); font-family: 'times new roman', times, serif; font-size: 12pt;"><strong>[Should you not want to receive any further emails, please reply to this email stating this. Also, provide any other email address that you might be using, to ensure that you do not receive any further emails from us].</strong></span></p>
<p class="MsoNormal"><span style="color: rgb(0, 0, 0);"><strong style="mso-bidi-font-weight: normal;"><span style="font-size: 10.0pt; line-height: 107%; font-family: 'Arial',sans-serif;">Disclaimer:</span></strong> <span style="font-size: 10pt; line-height: 107%; font-family: Arial, sans-serif; color: rgb(52, 73, 94);">This email and any attachments are intended only for the designated recipient(s). If you received this message by mistake, please inform the sender promptly and delete it from your system. We kindly ask you to refrain from using, sharing, or copying this email and its contents without authorization. Thank you for your understanding and cooperation.</span></span></p></p>
<img src='https://currentneuropharmacology.net/tracker.php?CampaignDataHash=0370e3fd51c01c228d60134d86ad4fef967044d72b0e21f910ac0085b350c4ca' alt='' style='display:none;' width='1' height='1'>
</div>
</body>
</html>